Luciferase reporter assay. 3x(-957T), 3x(-957C), 3x(-475C), 3x(-475T), 3x(+102G) and 3x(+102T) -luciferase reporter plasmids were generated by subcloning three repeats of a sequence containing the allelic variants from each SNP from the CCNB1 promoter into KpnI/XhoI-digested pGL3 promoter plasmid (Promega, Madison, Wisconsin). Supplemental Table X shows the sequence of each tandem repeat. U2OS cells were transiently transfected by the calcium phosphate method. Cells were co-transfected with 1µg of 3x(-957T), 3x(-957C), 3x(-475C), 3x(-475T), 3x(+102G) or 3x(+102T) and 0.1µg of pRL-TK Renilla (Promega) as a control for transfection efficiency. When indicated, cells were co-transfected with 1µg of pNF-YAm29 (encoding the NF-YA dominant-negative mutant) or the control pSG5 plasmid (gift from R. Mantovani, Milan, Italy), 1µg pEGFP-cFos or empty pEGFP, or 3 µg of pCMV-SP1 or empty pCMV, as indicated. One day after transfection, cell lysates were prepared and luciferase activity was measured with the Dual Luciferase Reporter Assay kit (Promega). Luciferase and GFP expression was measured in a Wallac 1420 Victor luminometer (Perkin Elmer, Waltham, MA).
Quantitative real-time PCR (qPCR).
Peripheral blood lymphocytes were obtained from 56 healthy donors who underwent a routine medical examination at Hospital Universitario Miguel Servet (Zaragoza, Spain) (see clinical characteristics in supplemental Table VIII) . 4 The local research committee approved the study and all subjects gave written informed consent. Cells were genotyped by the high resolution melting curves method in order to detect the two most frequent haplotypes: -957T/-475C/+102G (H1) and -957C/-475T/+102T (H2) (see supplemental Table V  and Table VII ). In total, 31 individuals had either H1 (n=14) or H2 (n=17). Peripheral blood mononuclear cells obtained by density gradient centrifugation 5 were washed twice with RPMI-1640 (Invitrogen), resuspended in complete RPMI-1640 (with GlutaMAX I, Invitrogen) containing 10% heat-inactivated FBS, Sigma) and 5 µg/ml PHA-M (Sigma), and plated at 2x10 6 cells/ml. After 24h, adherent cells were discarded and peripheral blood lymphocytes were maintained for 7d in RPMI-1640 supplemented with 10% FBS (37ºC, 5% CO 2 ). Cell viability assessed by trypan blue exclusion was >95%. Total RNA was isolated from lymphocytes using the RNeasy kit according to the manufacturer's instructions (Qiagen, Valencia, CA). RNA concentration and purity were assessed from the A260nm/A280nm ratio, and integrity was verified by separation on ethidium bromide-stained 1% agarose gels. RNA (0.5 to 2µg) was retrotranscribed using SuperScript III RNase H reverse transcriptase (Invitrogen). qPCR of lymphocytes was performed using FAM dye-labeled TaqMan MGB probes (Assay-on-Demand, RPLP0, Hs99999902_m1 and CCNB1, Hs00259126_m1) according to the manufacturer's recommendations (Applied Biosystems). CCNB1 mRNA levels were normalized to the housekeeping gene RPLP0. qPCR results were analyzed by the comparative Ct method. The numbers given for any MACE in the cumulative analysis do not equal the sum numbers given for each single event (death, myocardial infarction, repeat percutaneous coronary intervention: PCI) because some patients had more than one MACE. Myocardial infarction after the intervention was defined as either the development of pathologic Q waves lasting at least 0.4 second in at least two contiguous leads with an elevated creatine kinase MB isozyme level or, in the absence of pathologic Q waves, an elevation in total creatine kinase levels to more than twice the upper limit normal with elevated creatine kinase MB level. Target lesion revascularization (TLR) was defined as repeated revascularization to treat recurrent ischemia owing to stenosis of at least 50 percent of the luminal diameter anywhere within the stent or within the 5-mm borders proximal or distal to the stent. New lesion was defined as new critical (>70%) stenosis occurring in the same vessel (without the criteria for in-stent restenosis) or in other vessels in association with clinical signs or symptoms of ischemia. Only the upper strand of the double-stranded oligonucleotide is shown.
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